Stephen J. Schuster, MD, discusses the new milestones in therapy for the treatment of the B cell lymphomas, including de novo, relapsed/refractory, transformed, highi-risk, double-hit and frontline follicular lymphoma (FL) and marginal zone lymphoma (MZL). Therapies discussed include chimeric antigen modified t cell (CART, or CTL019) in relapsed/ refractory CD19+ follicular lymphoma and relapsed/refractory transformed FL; a new antibody, obinutuzumab, for prolongation of progression-free survival in FL; and ibrutinib in relapsed/refractory MZL.

Related Links: